XML 20 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues      
Revenues $ 8,757 $ 8,124 $ 8,434
Expenses      
Selling, general and administrative 2,917 2,625 2,624
Research and development 604 529 465
Amortization of intangible assets 1,077 1,215 1,375
Goodwill impairments 493 824 469
Asset impairments, including loss on assets held for sale 54 15 234
Restructuring, integration, separation and IPO costs 62 63 50
Other expense, net 28 35 373
Total Expenses 7,794 7,670 7,984
Operating income 963 454 450
Interest income 26 14 7
Interest expense (1,328) (1,464) (1,426)
Gain (loss) on extinguishment of debt 1 875 (62)
Foreign exchange and other (52) (8) 7
Loss before income taxes (390) (129) (1,024)
(Provision for) benefit from income taxes (221) (83) 87
Net loss (611) (212) (937)
Net loss (income) attributable to noncontrolling interest 19 (13) (11)
Net loss attributable to Bausch Health Companies Inc. $ (592) $ (225) $ (948)
Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share) $ (1.62) $ (0.62) $ (2.64)
Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share) $ (1.62) $ (0.62) $ (2.64)
Basic weighted-average common shares (in shares) 364,900 362,000 358,900
Diluted weighted-average common shares (in shares) 364,900 362,000 358,900
Product sales      
Revenues      
Revenues $ 8,663 $ 8,025 $ 8,328
Expenses      
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues 2,519 2,316 2,350
Other revenues      
Revenues      
Revenues 94 99 106
Expenses      
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues $ 40 $ 48 $ 44